AMERICAN JOURNAL OF PHARMTECH RESEARCH

Journal home page: http://www.ajptr.com/

In Silico Designing, Docking, ADME, Bioactivity and Toxicity Prediction of Novel 1, 4-Benzothiazine Derivatives as Potential Antihypertensive Agents

Amit Rai[1]*, Vinit Raj[1]

1.Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar Central Government University, Vidya Vihar, Raebreli Road, Lucknow-226025(U.P.), India

ABSTRACT

A series of substituted 1, 4-benzothiazine derivatives were designed keeping in view the structural requirement of pharmacophore and evaluated for *in silico* antihypertensive activity. Docking procedures allows virtually screening a database of compounds and predict the strongest binder based on various scoring functions. In the docking study, the most active compounds of the series was, AR 1, AR 2and AR 3 exhibited good binding properties. Result reveals that the protein-ligand interaction energy of derivatives AR 1, AR 2and AR 3 were -8.08 kcal/mol, -8.48 kcal/mol and -7.75 kcal/mol, which is better than the standard antihypertensive Losartan drug as -5.51 kcal/mol, so that the derivatives have satisfactory affinity with established hypertensive receptor namely Angiotensin converted enzyme 2. A computational study was also carried out including prediction of pharmacokinetic properties, toxicity and bioactivity studies. The percentage of absorption (%ABS) was calculated and observed that all titled compounds exhibited a great %ABS ranging 90.54, 91.42 and 90.54, with respectively and compared than standard Losartan drug as %ABS 77.06. These compounds emerged as a lead in this series and making them potentially promising agents for hypertension therapy.

Keywords:1, 4-benzothiazine derivatives, Anti hypertension activity, Computational study and ACE-2.

*Corresponding Author Email: raj.vinit24@gmail.com

Received 21 January 2014, Accepted 27 January 2014

Please cite this article in press as: Raj V *et al.*, *In Silico* Designing, Docking, ADME, Bioactivity And Toxicity Prediction of Novel 1, 4-Benzothiazine Derivatives as Potential Antihypertensive Agents. American Journal of PharmTech Research 2014.

INTRODUCTION

Hypertension or high blood pressure is a major risk factor for cerebro and cardiovascular disorder; therefore, blood pressure should be controlled and properly regulated in hypertensive patients[1]. Drugs available for the treatment of hypertension include diuretics, β-Blockers, aldosterone receptor antagonist, angiotensin converting enzyme (ACE) inhibitors and angiotensin-II receptor blockers (ARBs). Nonetheless, hypertension is poorly controlled in many patients and the drugs prescribed may produce significant side effects[2]. Angiotensin-I-converting enzyme (ACE) plays an important role in the regulation of hypertension. ACE catalyze the conversion of decapeptide (angiotensin-I) to the potent vasoconstring otapeptide (angiotensin II), inhibition of ACE activity leads to a decrease in the concentration of angiotensin II and consequently reduces blood pressure[3]. High blood pressure is associated with cardiovascular disease and organ damages[4]. It is regard as a silent killer; hypertension has a relationship with other cardiovascular disease. Increasing blood pressure increasing the risk developing other cardiovascular disease like stroke or coronary heart disease[5]. A part of search a new potassium channel opener [6, 6] fused ring system such as 1, 4-benzothiazine derivatives show the antihypertensive activity. 1, 4-benzothiazine derivatives are important molecules, which are common heterocyclic scaffold in biological activities like central nervous system depressant[6], calcium antagonist[7], antibacterial activity[8], and anti-tubercular activity[9].

Docking techniques have been used in modern drug designing to understand drug-receptor interaction. It has been shown in the literature that computational procedures may strongly support and help the design of new, more potent drugs by revealing the mechanism of drug-receptor interaction[10].

MATERIALS AND METHOD

For carrying out this, National centre for Biotechnology Information (NCBI) website and Protein Data Bank (PDB) website were used as chemical sources.

For designing the derivatives: Chemdraw Ultra 10.0

For optimizing the geometry of derivatives: ArgusLab software

For docking studies: Molegro Virtual docker and autodocking software

For characterization of the derivatives: Molinspiron software toolkit, MedChem Designer and EPA DSSTox Structure Browser v2.0 online service

Losartan structure data file was draw by Chemdraw Ultra 10.0 and protein target was downloaded from Protein Data Bank with PDB id 1R4L.

Protocol

Drawing of Losartan and AR 1, AR 2, AR 3 and AR 4 (Figure.1)

↓

Generation and geometry optimization of 3D structure

↓

Docking analysis of Losartan and 1, 4-benzothiazine derivatives with Inhibitor bound human Angiotensin converting enzyme-Related carboxypeptidase (ACE2)



Losartan



AR 1



AR 2



AR 3

Figure: 1 Show the chemical structure of standard Losartan drug and 1, 4-benzothiazine derivatives (AR 1, AR 2 &AR 3).

COMPUTATIONAL STUDY

A computational study of all compounds was performed for prediction of ADME properties such as absorption (%ABS), polar surface area (TPSA), miLog P etc by using Molinspiration property calculation toolkit. Docking study of titled compounds was performed with established hypertension molecular targets namely Angiotensin converting enzyme (ACE2), by using Autodock 4.0 and Argus lab software along with its LGA algorithm for automated flexible ligand docking and affinity (Kcal/mol).

Prediction of ADME properties

A computational study for prediction of ADME properties of titled compounds was performed. Topological polar surface area (TPSA), i.e., surface belonging to polar atoms, is a descriptor

thatwas shown to correlate well with passive molecular transport through membranes. The percentage of absorption was calculated using TPSA. From all these parameters, it can be observed that all titled compounds exhibited a great %ABS ranging. These all parameters was calculated using Molinspiration online property calculation toolkit[11]. The results are shown in Table 2. Absorption (%ABS) was calculated by:

% ABS = 109-(0.345×TPSA).[12]

Docking study

In this study, we have used Auto Dock 4.0 along with its LGA algorithm for automated flexible ligand docking of compounds AR 1, AR 2, AR 3 and Standard Losartan drug with one established hypertension molecular targets namely Angiotensin converted enzyme-II and evaluated docking affinity (Kcal/mol) and count of probable hydrogen bonds. All compounds have exhibited good binding properties (the comparison of protein-ligand interaction energy, much lower interaction energy is being associated with higher stability) compared than Losartan with receptor. The docking images are given in Figure: 2. The results are shown in Table: 1.



Figure: 2 It shows docking images (a) Losartan with ACE2 (1R4L), (b) AR1 with ACE2, (c) AR2 with ACE 2 and (d) AR 3 with ACE 2.

Bioactivity prediction and Toxicological comparative studies

The designed derivatives and original drug, bioactivity predictions have been compared along with some selected activity GPCR (G-Protein coupled receptor) etc. The score of bioactivity prediction of Losartan and 1, 4-benzothiazine derivatives (AR 1, AR 2& AR 3) are show in Table 3. The score of Toxological comparative studies of Losartan and 1, 4-benzothiazine derivatives (AR 1, AR 2& AR 3) are show in Table: 4. These all parameters was calculated using Molinspiration online property calculation toolkit and Lasar. in-silico toxicity prediction.

RESULTS AND DISCUSSION

Docking study

In this study, we have used Autodock 4.0 along with its LGA algorithm for automated flexible ligand docking of compounds **AR 1, AR 2** and **AR 3** with one established antihypertensive molecular target namely ACE-2and evaluated docking affinity (Kcal/mol). Compounds **AR 1, AR 2** and **AR 3** have exhibited good binding properties with Inhibitor bound human Angiotensin converting enzyme-Related carboxypeptidase (ACE2) (affinity value -8.08 kcal/mol, -8.48 kcal/mol and -7.75 kcal/mol with respectively) which is better than the standard antihypertensive Losartan drug (affinity value -5.51 kcal/mol). The docking images are given in Figure: 2 and the docking results are shown in Table: 1.

Table: 1 Table shows Protein-Ligand interaction Energy of Std. Losartan drug and 1, 4-benzothiazine derivatives, AR1, AR2, & AR3 with ACE2 (1R4L)

Sr. No.	Comp.	Est. Free Energy of Binding	Est. Inhibition Constant, Ki	vdW + Hbond + desolv Energy	Electrostatic Energy	Total Intermolec. Energy	Frequency	Interact Surface
1	**Losartan**	-5.51 kcal/mol	91.30 uM	-7.88 kcal/mol	-0.19 kcal/mol	-8.07 kcal/mol	20%	959.134
2	**AR1**	-8.08 kcal/mol	1.20 uM	-8.68 kcal/mol	-0.37 kcal/mol	-9.05 kcal/mol	60%	851.186
3	**AR2**	-8.48 kcal/mol	611.22 nM	-8.91 kcal/mol	-0.02 kcal/mol	-8.93 kcal/mol	60%	798.997
4	**AR3**	-7.75 kcal/mol	2.10 uM	-8.52 kcal/mol	-0.29 kcal/mol	-8.81 kcal/mol	50%	850.356

Predication of ADME properties

A computational study for prediction of ADME properties of titled compounds was performed. The percentage of absorption (%ABS) was calculated using TPSA. From all these parameters, it can be observed that all titled compounds exhibited a great %ABS ranging 90.54, 91.42 and 90.54 with respectively and compared than standard Losartan drug as %ABS 77.06 (Table: 2).

None of the compounds violated Lipinski's parameters, making them potentially promising agents for hypertension therapy.

Table: 2 Table shows ADME Properties Prediction of standard Losartan drug and 1,4-benzothiazine derivatives, AR 1, AR 2 & AR 3

S.No.		Rule	Losartan	AR 1	AR 2	AR 3
1	S+ log P	–	3.421	3.875	3.490	3.607
2	S +log D	–	1.269	3.615	3.490	3.420
3	M logP	–	3.667	2.985	3.154	2.748
4	M.Wt	< 500	422.920	323.419	307.392	309.392
5	n-OHNH donor	<5	2.000	2.000	1.000	2.000
6	M_NO.	–	7.000	4.000	4.000	4.000
7	T_PSA(Topological polar surface area)	_	92.570	53.490	50.950	53.490
8	Rule of 5	≤ 1	0.000	0.000	0.000	0.000
9	%ABS(% of absorption)	–	77.06	90.54	91.42	90.54
10	MV	–	465.001	407.583	349.459	351.475
11	n-ON acceptor	<10	7	4	4	4
12	Volume	–	423.74	389.57	313.40	323.39
13	n-ROTB	–	9	5	3	4

[a]**MlogP**, Moriguchi estimation of logP. S+ log P logP calculated using Simulations Plus' highly accurate internal model; **S+logD**, logD at user-specified pH (default 7.4), based on S+logP;**n-OHNH donor**, Number of Hydrogen bond donor protons; **M_NO**, Total number of Nitrogen and Oxygen atoms; **T_PSA**, Topological polar surface area in square angstroms; **Rule Of Five**, Lipinski's Rule of Five: a score indicating the number of potential problems a structure might have with passive oral absorption; miLog P, logarithm of compound partition coefficient between n-octanol and water; log D, logarithm of compound distribution coefficient; n-ROTB, number of rotatable bonds; MV, molecular volume; n-ON acceptor, number of Hydrogen bond acceptor protons.

Bioactivity prediction and Toxological comparative studies

In this study, for prediction of Bioactivity and Toxological properties of titled compounds was carried out. From all calculated parameters, it can be observed that all titled compounds compared than standard Losartan drug shown less affinity with GPCR(G-Protein coupled receptor) ligand, Ion channel Modulator, Kinase inhibitor, Kinase inhibitor, Nuclear receptor ligand, Protease inhibitor and Enzyme inhibitor and the toxological comparative studies of all titled compounds compared than standard Losartan drug having very less toxicity effect such as acute toxicity to fish (lethality), carcinogenicity, mutagenicity and repeated dose toxicity that mean these compounds can be make good bioactivity and minor toxicity drug compared than

standard Losartan drug for hypertension. The Bioactivity and Toxological data are given in Table 3-4.

Table: 3 Table shows score of bioactivity prediction of Losartan and 1,4-benzothiazine derivatives, AR 1, AR 2 & AR 3.

S.No.		Losartan	AR 1	AR 2	AR 3
1	GPCR(G-Protein coupled receptor) ligand	0.98	-0.13	-0.05	-0.28
2	Ion channel Modulator	0.19	-0.47	-0.25	-0.72
3	Kinase inhibitor	0.02	-0.47	-0.14	-0.46
4	Nuclear receptor ligand	0.01	-0.17	-0.13	-0.43
5	Protease inhibitor	0.33	-0.29	-0.16	-0.52
6	Enzyme inhibitor	0.43	-0.30	-0.09	-0.46

Table: 4 Table shows score of Toxological comparative studies of Losartan and 1,4-benzothiazine derivatives, AR 1, AR 2 & AR 3.

S.No.		Losartan	AR 1	AR 2	AR 3
1	DSSTox Carcinogenic Potency DBS Multi Cell Call: non-carcinogen	0.00859	0.0143	0.0641	0.0143
2	DSSTox Carcinogenic Potency DBS Mutagenicity: non-mutagenic	0.0695	0.0357	0.0221	0.0357
3	DSSTox Carcinogenic Potency DBS Rat: non-carcinoge	0.0416	0.0488	0.0515	0.0446
4	Kazius-Bursi Salmonella mutagenicity: non-mutagenic	0.0422	0.0303	0.0371	0.0303
5	FDA v3b Maximum Recommended Daily Dose mmol: 0.0152722115276765	0.219	0.0878	0.106	0.0926
6	DSSTox Carcinogenic Potency DBS Single Cell Call: non-carcinogen	0.0106	0.042	0.0222	0.0278
7	EPA v4b Fathead Minnow Acute Toxicity LC50_mmol: 0.00359162218026281	0.164	0.168	0.195	0.195
8	DSSTox ISSCAN v3a Canc: carcinogen	0.0394	0.0533	0.0621	0.0533
9	DSSTox Carcinogenic Potency DBS Hamster: non-carcinogen	0.108	0.165	0.19	0.165
10	DSSTox Carcinogenic Potency DBS Mouse:non-carcinogen	0.153	0.0696	0.067	0.0696

CONCLUSION

A series of novel 1, 4-benzothiazine derivatives were designed and a computational study was also carried out including docking studies, ADME, bioactivity and toxicity prediction of titled compounds. All compounds displayed significant binding affinity compared than the standard antihypertensive drug and very less toxicity found. The docking study data strongly support the assumption that this receptor may be involved in observed antihypertensive activity of 1, 4-benzothiazine derivatives. However further studies need to be carried out to synthesis, *in-vivo*

evaluation of pharmacological activity and ascertain the precise mechanism of action of antihypertensive activity of these compounds. These titled compounds emerged as a lead in this series and making them potentially promising agents for hypertension therapy.

ACKNOWLEDGEMENTS

The authors would like to express their gratitude to Babasaheb Bhimrao Ambedkar Cental Government University Lucknow for providing the software and research data. The authors also appreciate the help and support by Mr. Vinit Raj (Research scholar at BBAU Lucknow) during docking study.

REFERENCE

1. FitzGerald RJ, Murray BA, Walsh DJ. Hypotensive peptides from milk proteins. J Nutr 2004; 134: 980S–8S.
2. Moiz MS, Dileep VM, Ronald GV. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive. Drug Am. J. Med 2008; 121: 265–271.
3. Ehlers MR, Fox EA, Strydom DJ, Riordan JF. Molecular cloning of human testicular angiotensin-converting enzyme: the testis isozyme is identical to the C-terminal half of endothelial angiotensin-converting enzyme. Proc. Natl. Acad. Sci. USA1989; 86: 7741-7745.
4. Adel Girgis S, *et.al.* Ragio selective synthesis and molecular modeling study of vaso relaxent active 7, 9-diaza-spiro [4.5] dec-2-ene-6,10-diones. European journal of medicinal chemistry 2010; 45: 4229-4238.
5. Obinna lkechukwu Ekwunife *et. al.* Cost-utility analysis of antihypertensive medications in Nigeria: a decision analysis, cost effective and resource allocation 2013; 11: 2.
6. Renata F,*et.al*.1,4-benzothiazine analogues and apoptosis: structure-activity relationship. Bioorganic & medicinal chemistry II 2003; 3245-3254.
7. Kajino M, *et.al.* Synthesis and biological activities 1,4-benzothiazine derivatives. Chem Pharma bull (Tokyo) 1991; Nov.39(ii): 2888-95.
8. Vera L, de Guarda M,*et.al.* Synthesis of 4-octyl-2H-1, 4-benzothiazine-3-ones. European Journal of medicinal chemistry2003; 38: 769-773.
9. Chao Gao *et.al.* Synthesis and structure-activity relationship evolution of benzothiazine derivatives as potential anti-tubercular agent. Bioorganic & medicinal chemistry letters 2013; 23: 4919-4922.

10. Srivastava V, Kumar A, *et.al.* Molecular docking studies on DMDP derivatives as human DHFR inhibitors. Bioinformation 2008;3(4):180-188.
11. Molinspiration Cheminformatics, Bratislava, SlovakRepublic, Available from: http://www.molinspiration.com/services/properties.html[accessed 16.08.2010].
12. Zhao Y, Abraham MH, Lee J, Hersey A, Luscombe NC, Beck G, Sherborne BI. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res2002; 19:1446–1456.

AJPTR is

- **Peer-reviewed**
- **bimonthly**
- **Rapid publication**

Submit your manuscript at: editor@ajptr.com